BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects. Int J Mol Sci 2021;22:3464. [PMID: 33801659 DOI: 10.3390/ijms22073464] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Pereira JFS, Jordan P, Matos P. A Signaling View into the Inflammatory Tumor Microenvironment. Immuno 2021;1:91-118. [DOI: 10.3390/immuno1020007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Guney Eskiler G, Ozturk Sezgin M. Therapeutic potential of the PI3K inhibitor LY294002 and PARP inhibitor Talazoparib combination in BRCA-deficient triple negative breast cancer cells. Cell Signal 2021;91:110229. [PMID: 34958867 DOI: 10.1016/j.cellsig.2021.110229] [Reference Citation Analysis]
3 Mussa A, Carli D, Cardaropoli S, Ferrero GB, Resta N. Lateralized and Segmental Overgrowth in Children. Cancers (Basel) 2021;13:6166. [PMID: 34944785 DOI: 10.3390/cancers13246166] [Reference Citation Analysis]
4 Elfeky SM, Almehmadi SJ, Tawfik SS. Synthesis, in-silico, and in-vitro study of novel chloro methylquinazolinones as PI3K-δ inhibitors, cytotoxic agents. Arabian Journal of Chemistry 2022;15:103614. [DOI: 10.1016/j.arabjc.2021.103614] [Reference Citation Analysis]
5 Peng Y, Wang Y, Zhou C, Mei W, Zeng C. PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway? Front Oncol 2022;12:819128. [DOI: 10.3389/fonc.2022.819128] [Reference Citation Analysis]
6 Almasri M, Amer M, Ghanej J, Mahmoud AM, Gaidano G, Moia R. Druggable Molecular Pathways in Chronic Lymphocytic Leukemia. Life 2022;12:283. [DOI: 10.3390/life12020283] [Reference Citation Analysis]
7 Borsari C, Keles E, McPhail JA, Schaefer A, Sriramaratnam R, Goch W, Schaefer T, De Pascale M, Bal W, Gstaiger M, Burke JE, Wymann MP. Covalent Proximity Scanning of a Distal Cysteine to Target PI3Kα. J Am Chem Soc 2022. [PMID: 35353516 DOI: 10.1021/jacs.1c13568] [Reference Citation Analysis]
8 Piazzi M, Bavelloni A, Cenni V, Salucci S, Bartoletti Stella A, Tomassini E, Scotlandi K, Blalock WL, Faenza I. Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strategy in Human Rhabdomyosarcoma Cells. Molecules 2022;27:2742. [DOI: 10.3390/molecules27092742] [Reference Citation Analysis]
9 Heudel P, Frenel JS, Dalban C, Bazan F, Joly F, Arnaud A, Abdeddaim C, Chevalier-Place A, Augereau P, Pautier P, Chakiba C, You B, Lancry-Lecomte L, Garin G, Marcel V, Diaz JJ, Treilleux I, Pérol D, Fabbro M, Ray-Coquard I. Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial. JAMA Oncol 2022. [PMID: 35551299 DOI: 10.1001/jamaoncol.2022.1047] [Reference Citation Analysis]
10 Yang H, Li Q, Su M, Luo F, Liu Y, Wang D, Fan Y. Design, synthesis, and biological evaluation of novel 6-(pyridin-3-yl) quinazolin-4(3H)-one derivatives as potential anticancer agents via PI3K inhibition. Bioorg Med Chem 2021;46:116346. [PMID: 34403956 DOI: 10.1016/j.bmc.2021.116346] [Reference Citation Analysis]
11 Setlai BP, Hull R, Bida M, Durandt C, Mulaudzi TV, Chatziioannou A, Dlamini Z. Immunosuppressive Signaling Pathways as Targeted Cancer Therapies. Biomedicines 2022;10:682. [DOI: 10.3390/biomedicines10030682] [Reference Citation Analysis]
12 Cháirez-Ramírez MH, de la Cruz-López KG, García-Carrancá A. Polyphenols as Antitumor Agents Targeting Key Players in Cancer-Driving Signaling Pathways. Front Pharmacol 2021;12:710304. [PMID: 34744708 DOI: 10.3389/fphar.2021.710304] [Reference Citation Analysis]